Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 70116152 | Other Grant/Funding Number | Deutsche Krebshilfe |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| German Sarcoma Foundation (DSS) | UNKNOWN |
| German Cancer Research Center | OTHER |
| Universitätsmedizin Mannheim | OTHER |
| University Hospital, Essen |
Not provided
Not provided
Not provided
Not provided
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Sarcomas are rare cancers that can arise almost anywhere in the body and account for only about one percent of all cancer diagnoses. Both the disease and its treatments often result in late effects, yet knowledge about these long-term consequences remains limited. The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. Particular focus is placed on subgroups with potential long-term risks, including survivors of bone sarcomas, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, gastrointestinal stromal tumors (GIST) with or without long-term TKI therapy, and young adult survivors.
The mixed-methods research design includes a multicenter observational study with a one-time questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Recruitment is built on draws on existing network structures, including the PROSa cohort, the National Center for Tumor Diseases (NCT/UCC) Dresden, the SarcBOP registry at the National Center for Tumor Diseases (NCT) Heidelberg, West German Cancer Center Essen (WTZ), University Hospital Mannheim (UMM), the German Sarcoma Foundation, and cooperating sarcoma centers. Medical data are extracted from patient records.
Statistical analyses will include descriptive statistics and regression models to identify impaired quality of life domains and associated factors.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sarcoma survivors | Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention (observational study) | Other | No intervention (observational study) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life (EORTC QLQ-SURV100) | The EORTC QLQ-SURV100 is a 100-item questionnaire assessing general quality of life among cancer survivors. It includes multiple functional scales covering physical, role, emotional, cognitive, and social functioning, as well as symptom scales (fatigue, pain) and several single-item measures. Most items are rated on a 1-4 scale, while two global items on overall quality of life and general health are rated on a 1-7 scale. Higher scores on the functional and global health status scales indicate better quality of life, whereas higher scores on symptom scales reflect worse quality of life. With the exception of five acute symptoms, the SURV100 includes all items from the EORTC QLQ-C30. To enable comparative analyses, the investigators supplemented the SURV100 with these five missing items: appetite loss, nausea, vomiting, constipation, and diarrhea. | single-time point (enrollment) |
| Satisfaction with Medical Care (adapted from EORTC OUT-PATSAT7 & self-developed items) | Satisfaction with medical care and communication will be assessed using three items adapted from the EORTC OUT-PATSAT7 and three self-developed items, all rated on a 1-5 scale. Higher scores indicate greater satisfaction with the medical care received. | single time point (enrollment) |
| Use of Care Offers (self-developed, adapted from CaSUN) | Service utilization will be assessed with self-developed items based on the Cancer Survivors' Unmet Needs measure (CaSUN). Participants indicate their use of 24 different non-rehabilitation care services and 11 rehabilitation care services. Response options include two types of "No" (offer not available or offer available but not used) and, if "Yes," a rating from 1-3 indicating how helpful the offer was, with higher scores reflecting greater helpfulness. | single time point (enrollment) |
| Unmet Needs (self-developed, adapted from CaSUN) | Unmet needs will be assessed with self-developed items based on the CaSUN, asking participants about the lack of adequate support or services in 20 areas. Response options include two types of "No" (no need or need has already been met) and, if "Yes," a rating from 1-3 indicating the current intensity of the unmet need, with higher scores reflecting greater unmet need. |
| Measure | Description | Time Frame |
|---|---|---|
| Fatigue (EORTC QLQ-FA12) | Fatigue will be assessed using the 12-item EORTC QLQ-FA12 scale, which measures physical, emotional, and cognitive aspects of cancer-related fatigue on a 1-4 scale. Higher scores indicate greater fatigue. | single-time point (enrollment) |
| Psychological Distress (PHQ-4) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tanja Strukelj, M. A. | Contact | +493514587056 | tanja.strukelj@ukdd.de, | |
| Patricia Blickle, M. Sc. | Contact | +49221423506 | patricia.blickle@dkfz-heidelberg.de |
| Name | Affiliation | Role |
|---|---|---|
| Martin Eichler, Dr. | TU Dresden & NCT/ UCC Dresden | Principal Investigator |
| Karen Steindorf, Prof. Dr. | DKFZ Heidelberg | Principal Investigator |
| Richard F. Schlenk, Prof. Dr. |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Technical University Dresden | Recruiting | Dresden | Saxony | Germany |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D012509 | Sarcoma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D019370 | Observation |
| ID | Term |
|---|---|
| D008722 | Methods |
| D008919 | Investigative Techniques |
Not provided
Not provided
| OTHER |
| National Centre for Tumor Diseases Heidelberg | UNKNOWN |
Not provided
Not provided
Not provided
| single time point (enrollment) |
Psychological distress will be measured using the four-item PHQ-4, including the diagnostic core criteria for depression (PHQ-2) and generalized anxiety disorder (GAD-2), ranging from 1-4. Higher scores indicate greater psychological distress. |
| single-time point (enrollment) |
| Loneliness (UCLA LS-3) | Loneliness will be assessed using the three-item UCLA Loneliness Scale, measuring subjective feelings of loneliness and social isolation, ranging from 1-3. Higher scores indicate greater loneliness. | single-time point (enrollment) |
| Physical Complaints (EORTC WISP) | Physical complaints will be measured using the EORTC WISP module, allowing participants to report up to three symptoms and rate the degree of burden from 1-4. Higher scores indicate greater impairment due to the respective symptom. | single-time point (enrollment) |
| Communication with Healthcare Professionals (adapted from EORTC COMU26 & self-developed items) | Communication experiences will be assessed using nine items adapted from the EORTC COMU26 and nine self-developed items, focusing on perceived quality and clarity of communication with healthcare providers. Rated on a 1-4 scale, higher scores indicate greater satisfaction with communication. | single-time point (enrollment) |
| Information Sources (self-developed, answer options adapted from CaSUN) | Information sources will be assessed using nine self-developed items, asking participants where they obtain cancer-related information. Response options include two types of "No" (not known or known but not used) and, if "Yes," a rating from 1-3 indicating how helpful the source was, with higher scores reflecting greater helpfulness. | single-time point (enrollment) |
| Sociodemographic Items | Sociodemographic characteristics, including age, sex, and migration background will be collected. | single-time point (enrollment) |
| Socioeconomic Items | Socioeconomic status will be assessed through items measuring i.a. education, employment status, and income. | single-time point (enrollment) |
| Physical Activity (adapted Godin-Shephard Leisure-Time Physical Activity Questionnaire) | Physical activity will be measured using an adapted version of the Godin-Shephard Leisure-Time Physical Activity Questionnaire. This 4-item questionnaire evaluates the frequency and duration of mild, moderate and vigorous aerobic activities, as well as moderate-to-vigorous strength training, performed during the week. Scores reflect whether participants meet exercise guidelines:
| single-time point (enrollment) |
| Comorbidities | Information on comorbid conditions (e.g., cardiovascular disease, diabetes, depression) will be collected, capturing co-existing health conditions. The total number of comorbidities will be summed and used as a control variable in the analyses. | single-time point (enrollment) |
| University Hospital Heidelberg |
| Principal Investigator |
| Jens Jakob, Prof. Dr. | Sarcoma Center Mannheim | Principal Investigator |
| Uta Dirksen, Prof. Dr. | University Hospital, Essen | Principal Investigator |
| Markus Wartenberg | Deutsche Sarkom-Stiftung | Principal Investigator |
| University Hospital Essen | Not yet recruiting | Essen | Germany |
|
| NCT Heidelberg | Recruiting | Heidelberg | Germany |
|
| Sarcoma Center Mannheim | Recruiting | Mannheim | Germany |
|
| Deutsche Sarkom-Stiftung | Recruiting | Wölfersheim | Germany |
|